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Introduction
Despite the first report of cancer being found in ancient Egypt,
and since then an enormous knowledge improvement has
been achieved, the patient’s prognosis is still unsatisfactory.
Cancer is the second leading cause of death exceeded only by
heart disease. According to theUnited States Cancer Statistics
Incidence and Mortality Web-based Report, in 2014 every
minute someone will die of cancer in the United States.
Among malignancies, breast cancer is the most common
tumour in the United States and Europe. Each year more than
1.3 million women worldwide are diagnosed with breast
cancer and approximately 458,400 die from the disease
(American Cancer Society 2011) despite the fact that breast
cancer is highly curable if diagnosed and treated appropriately
at an early stage. Annual breast cancer mortality has slightly
decreased, however it is mainly related with an improvement
of early diagnosis. Unfortunately in case of advanced tu-
mours, medicine is powerless. The poor statistics and out-
comes in mammary cancer patients make this tumour one of
the most investigated in humans and domestic animals
species.
In the bitch the incidence of mammary tumour is even three
times over than in human (MacEwen 1990). About 50% of all
mammary tumours are malignant (Midsorp 2002). The inci-
dence of mammary tumours is estimated at 31.8 and 20.4 in
100,000 uncastrated and castrated cats, respectively.
Malignant neoplasms are found even more often in queens
compared to neoplasms in bitches (MacEwen 1990; Midsorp
2002). Mammary tumours are very rare in other species. They
have been reported sporadically in horses and only a few cases
are known in ruminants and swine.
Epidemiology of mammary cancer in dogs and cats is
similar to breast cancer. Humans and dogs have lived in
similar environmental conditions for thousands of years;
sometimes they even have a similar diet. Canine and human
mammary tumours are usually of epithelial origin, they are
also hormone-dependent. Moreover, in both species they oc-
cur spontaneously, in contrast to inducible or implantable
mammary tumours in laboratory animals (Midsorp 2002).
Comparative gene expression studies
One of the goals of the National Cancer Institute’s
Comparative Oncology Program (NCI-COP) in the USA is
to include companion animals with cancer in the mainstream
of cancer research. It is easier to obtain samples from the dog
than from laboratory animals (e.g. blood, urine, RTG). An
important advantage of this model is the high similarity in the
P450 cytochrome activity between dogs and humans.
Location of P450 is not only limited to the liver, but they
can be found also in other tissues, including cancer. Enhanced
expression in tumour cells of these enzymes increases the
potential for metabolism of anticancer drugs by the tumour
cells directly. In chemotherapy, metabolism of drugs is per-
formed at the site of the tumour, in a liver, or a combination of
both (McFadyen et al. 2004). Thus, it is believed that results
obtained in dogs can be more reliable for human medicine
than results obtained in rodents. This is why the dog can
constitute an intermediate stage between rodents and humans
in clinical trials.
To follow aims of the American National Cancer Institute,
Briggs et al. (2011) established a database of canine normal
tissue gene expression data. It became possible after the public
release of the canine genome project in 2005 (Lindblad-Toh
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et al. 2005). This genomic sequencing data, together with the
development of canine-specific microarrays, provided the op-
portunity to conduct that kind of ‘omic’ studies in Canis lupus
familiaris. Briggs and co-workers found tissue-specific gene
expression profiles. Moreover, they have found similarities
between gene expression patterns in canine and human
healthy tissues. In both species, each organ could be clustered
in a manner consistent with anatomical function and/or cellu-
lar composition (Briggs et al. 2011).
Several other studies cited below showed the same gene
expression patterns and pathway alterations in human and
animal cancers. These results confirm that dogs are good
models to study spontaneous tumours in humans. An excel-
lent study was conducted by Uva et al. (2009). The authors
showed a close similarity between human and dog mammary
tumours regarding the perturbation of many cancer-related
gene sets and pathways, e.g.: PI3K/AKT, KRAS, WNT-beta
catenin and MAPK, as well as a group of genes specific for
cancer stem cells. Their data emphasized a high potential
value of the dog as a preclinical model to test therapeutic
agents because many of modern anticancer drugs target spe-
cific intracellular pathways. Importantly, their data also sug-
gest the possibility of the reverse path, i.e. development of
transcriptional biomarkers in dogs to be applied subsequently
to humans.
Similarly, in both species: in dogs and humans, an up-
regulation of the same ribosomal proteins in meningioma
was detected (Thomson et al. 2005). This data show that
canine brain tumours undergo similar genetic changes to those
of human brain tumours on a molecular level. The similarity
between both species seems to also be observed in lymphoma
as in both species the co-expression clusters of NF-κB, p53,
JAK/Stat and PI3K/AKT signalling pathways were found
(Mudaliar et al. 2013). In addition, up-regulation of IL-10,
IL-6 and IL-2 in canine lymphoma supported a role for in-
flammatory pathways maintaining the malignant phenotype
(as observed in humans) and suggested that there may be
common therapeutic targets in both species. Thus, canine
lymphoma may represent a natural model of human disease
and may offer a system to advance novel compounds to the
clinic (Mudaliar et al. 2013).
Nowadays the possibility of full sequencing of cancer
genome gives more research opportunities. An interesting
study has been conducted by Navin et al. in 2011. They
sequenced 100 single cells sorted from a heterogenous
tumour and revealed four distinct groups of genomes.
Sequencing is still a costly process, however technology
is improving fast and demands are continuously de-
creased. International consortia perform large-scale anal-
ysis of cancer genomes that will provide in the future
essential information on the landscape of cancer genomes
(Vollan and Caldas 2011). Probably first reports of ani-
mal cancer genomes will be also published soon.
Oncogenomics in diagnostics
Nowadays in all species challenges still prevail in the early
diagnosis and management of cancer patients, due to unpre-
dictability, in many cases, follow-up and response to adjuvant
therapies. Despite wide availability of a variety of diagnostic
methods (mammography, USG, RTG, CT, MR, PET), the
microscopic examination still constitutes the most important
one. Unfortunately, in most cases the value of histological
prognostic indicators in predicting the course of a disease is
weak. The histological diagnosis considers mainly the mor-
phological properties of the tumours, however it does not
account for the molecular mechanisms underlying cancer
progression. For example, for some tumours the surgical
removal of the primary tumour might be curative and the
systemic therapy to eliminate any remaining tumour cells is
not required. In other cases aggressive systemic chemotherapy
is required after tumour resection. However, the pathological
distinction between these cases is often unclear (van’t Veer
and Bernards 2008). That is why investigators are nowadays
focused on discovering novel predictive markers for different
types of cancer. Such biomarkers are important to improve
patient management. Scientists and physicians understood
that the cancer therapy needs to change to a more personalized
approach, in which each patient is treated according to the
specific genetic defects in the tumour (van’t Veer and
Bernards 2008) (Fig. 1). This breakthrough was possible due
to the availability of large data sets about the gene expression
in various tumours. An American group published a ‘mile-
stone’ study in breast cancer describing four different molec-
ular portraits of this disease representing the ‘tumour type’
itself, not only the particular tumour ‘sample’ (Perou et al.
2000). Based on the gene expression, the authors found four
groups of tumours that might be related to different molecular
features of mammary epithelial biology (ER+/luminal-like,
basal-like, Erb-B2+ and normal breast). The most important
point of this study was the clinical designation of two biolog-
ically distinct subtypes of tumours (which were previously
classified as the same type), which should be treated as distinct
diseases (Perou et al. 2000). Then, the 21-gene real-time rt-
PCR-based assay has been patented as ‘Oncotype DX’ and
used for tailoring the chemotherapy protocols in lymph-node-
negative, ER-positive patients at early stage breast cancer
(Hornberger et al. 2005).
The Dutch group went a step further and discovered a gene
expression profile associated with the risk of early develop-
ment of distant metastasis in young patients with lymph-node
negative breast cancer (van’t Veer et al. 2002; van de Vijver
et al. 2002). In this group of patients recurrence is likely in 20–
30 % if surgery and localized radiation treatment are applied
(van’t Veer et al. 2002; van’t Veer and Bernards 2008; van de
Vijver et al. 2002). However, according to the European and
American guidelines, about 85 % of women with this type of
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cancer undergo chemotherapy, mostly because conventional
pathological parameters fail to reliably identify those patients
who are likely to relapse. Therefore, 55–65 % of women with
node-negative breast cancer are subjected to a toxic therapy
from which they will not benefit but furthermore they will
experience side effects (van’t Veer et al. 2002; van’t Veer and
Bernards 2008; van de Vijver et al. 2002). Their microarray
diagnostic test (patented as ‘MammaPrint’) based on 70-gene
expression patterns was established as a powerful predictor of
disease outcome in young breast cancer patients and to im-
prove the guidance for the requirement of adjuvant therapy
(van’t Veer et al. 2002; van’t Veer and Bernards 2008; van de
Vijver et al. 2002; Glas et al. 2006) (Fig. 1). Personalized
medicine can help to avoid unnecessary chemotherapy treat-
ment and reduce the healthcare costs. However, at this mo-
ment the patient genotype information is not commonly in-
cluded in treatment of breast cancer (Vizirionakis 2014).
In veterinary oncology personalized medicine is not used at
all. However, some studies gave very promising results which
bring hope for introducing modern diagnostic tests into the
clinical settings in the future. For example, Monks et al.
showed in 2013 that it is possible to provide a ‘personalized’
drug sensitivity and drug response signatures report of canine
osteosarcoma to the veterinarian in five days from receipt of a
sample. The group of Fowles have recently (2013) examined
co-expression extrapolation (COXEN) method’s utility in a
cross-species extrapolation of gene expression models
(GEMs) to predict chemosensitivity for six anticancer drugs
in canine osteosarcoma based on a human reference set. The
GI50 ranges for all six drugs were comparable to the ranges
calculated for the canine samples. COXEN analysis generated
GEMs for each drug that on average were 79 % accurate in
predicting sensitivity in the canine. Their analysis was also
73 % accurate in predicting disease free interval in canine
osteosarcoma patients. Thus, they found that COXEN can be
useful in cross-species prediction models and for future use in
veterinary clinical trials.
The group of Dr Jan A. Mol from The Netherlands has
designed a molecular-based method for discrimination of
short and long survivors in canine patients with osteosarcoma.
The authors showed that genes associated with cell cycle/
proliferation, drug resistance and metastasis were commonly
overexpressed in short survivors. Heat-shock proteins have
been identified as involved in osteosarcoma development for
both humans and dogs (Selvarajah et al. 2009). Comparison of
the most important pathways for osteosarcoma development
in humans and dogs revealed overlapping of seven of them,
including Wnt, chemokine/cytokine, Alzheimer disease-
presenilin pathway, fibroblast growth factor (FGF), platelet
derived growth factor (PDGF), apoptosis and interleukin sig-
naling pathways.
In the case of mammary cancer Klopfleisch et al. (2010)
identified a gene expression profile of canine mammary tu-
mours which was associated with an early metastatic spread to
the lymph nodes. This differential expression profile contains
several enriched functional gene classes and has 60 % overlap
with expression profiles of metastatic human breast cancer
described by the Dutch group (‘Mammaprint’). Metastatic
tumours were characterized by increased expression of cell
division genes and decreased expression of genes involved in
focal adhesion. The dysregulation of cell cycle control is
therefore a dominant feature of metastatic mammary tumours
in various species.
In the case of canine mammary cancer, not only prediction
of metastasis is important, but also the distinction between
various grades of tumours. In veterinary medicine identifica-
tion of ‘truly’ malignant tumours constitutes a real problem
(Goldschmidt et al. 2011). The most significant criteria for the
diagnosis of canine mammary malignancy are as follow:
tumour type, nuclear and cellular pleomorphism, mitotic in-
dex, presence of randomly distributed areas of necrosis within
the neoplasm, blood and lymphatic vessels invasion, and
Fig. 1 Personalized approach to medicine is based on the perturbations
in a single cell genome or proteome and can help to decide which patients
to treat and how they should be treated
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regional lymph node metastasis. Unfortunately, classification
based on these criteria sometimes leads to the over-diagnosis
of mammary carcinoma (Goldschmidt et al. 2011) especially
due to significant human factors that may influence these
results. As the highest grade of malignancy is associated with
an increased risk of death within 2 years after mastectomy
(Karayannopoulou et al. 2005), proper diagnosis may lead to
prediction of the clinical outcome. Thus, our group performed
gene expression analysis of canine mammary tumours of
various grade of malignancy in order to find molecular
markers of canine mammary malignancy (that could help to
improve pathological diagnosis of the tumour grade). We have
built the molecular classifier, which was able to distinguish the
most malignant canine mammary tumours from the lowest
estimated malignant tumours (Pawłowski et al. 2013a, b, c).
Thus, based on the expression pattern of the sehrl, zfp37,
mipep, relaxin, and magi3 the pathologist could clearly dis-
tinguish grade III tumours which are correlated with poor
prognosis. Optimization of this method is still in progress.
Targeted therapy
Poor cancer statistics demonstrate the necessity of newer
therapeutic modalities for achieving successful cancer treat-
ment and cure. Knock-down of genes that contribute to cancer
progression has been the goal of targeted genomics-based
strategies, with the hope to selectively inhibit tumour growth
with minimal side effects on normal cells. This has led to a
recent acceleration in the development and optimization of
tailored strategies for cancer therapy (Devi 2006). Targeted
therapy has a great potential in oncology, but resistance to the
agents is a significant clinical problem. For example, in colo-
rectal cancer, it has been shown that treatment with Cetuximab
(an EGFR inhibitor) is ineffective in the presence of an acti-
vating mutation of k-ras (Vollan and Caldas 2011). Another
important mechanism of cancer cell self-protection is through
the activity of multiple drug resistance transporters. This is
frequently associated with over-expression of two or more
membrane pumps which efflux anticancer drugs from the
cytoplasm. These pumps protect tumour cells against the drug
effects and correlated molecular processes. As increased ef-
flux is such a significant contributor to a multidrug resistance
in cancer cells, current research is aimed at blocking or
inhibiting this specific mechanism. Because treatment of can-
cer cells with the use of classical inhibitors of efflux pumps
often fails, we used a novel approach, that is: the specific
RNAi to knock-down their expression (Pawłowski et al.
2013d). We showed that silencing of the efflux pumps had
significant influence on cancer cell susceptibility to cytostatic
drugs (determined based on the IC50 doses). Comparison of
IC50 doses of anticancer drugs given in vitro and their max-
imum possible plasma concentrations showed that the bcrp,
mrp1 or mrp3 knock-down can reverse cancer drug-
resistance. Targeting of efflux pumps expression during che-
motherapy could reduce the risk of anticancer drugs side
effects by decreasing their doses. Our research is a completely
new approach in the field of veterinary oncology. Despite the
useful function of RNAi therapeutics for disease treatment, it
still requires the development of clinically suitable, safe and
effective drug delivery vehicles, there are some promising
data from ongoing clinical trials that give hope for their
practical application in the future (Pawłowski et al. 2013d).
A similar approach was used by Perez et al. (2011) who
showed that inhibition ofMDR1 reversed inherent or acquired
resistance to critical cytotoxic compounds for the treatment of
cancer. Moreover, this approach allowed to lower chemother-
apy doses maintaining tumour control. This is particularly
relevant for paediatrics tumours where chemotherapy cures
should be associated with minimum if no impact at all on
long-term quality of life.
To sum up, there is a need of practical clinical utility of
personalized medicine, especially in oncology (Vizirionakis
2014). Importantly as it has been recently proposed, by cross-
ing the borderlines of genomics with nanotechnology and thus
creating the necessary framework and infrastructure, the prac-
tical clinical utility of personalized medicine could be better
served and advanced in a feasible and cost-affordable manner
(Vizirianakis and Fatouros 2012). These efforts should be
supported by the collaboration between companies, policy
makers, research institutes, and hospitals (Yu et al. 2010).
Nevertheless, proof will be required that ‘omics’-based per-
sonalized medicine generate an overall cost reduction before
such an approach can finally fulfil the high expectations it has
raised.
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